Immorna is a rapidly expanding biotechnology company, focusing on the development of mRNA-based therapeutics and vaccines. Immorna is utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA.
Since it’s founding in 2019, Immorna has built a robust CMC platform for mRNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of mRNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery.
Immorna has a growing intellectual property portfolio and a diverse mRNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology and infectious disease drug candidates into their clinical stages.
Company Details
- Employees
- 23
- Founded
- 2019
- Address
- 635 Davis Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.immorna.com
- HQ
- Morrisville, North Carolina
Immorna Questions
Immorna's website is http://www.immorna.com
Immorna's LinkedIn profile is https://www.linkedin.com/company/immorna
Immorna has
23 employees.
View email and phone details for 23
employees at Immorna.
Immorna's industry is
Biotechnology Research
Immorna's top competitors are
Stridebio, Inc,
Immunomic Therapeutics, Inc.,
Locus Biosciences, Inc.,
Ribometrix Inc.,
Candel Therapeutics,
Precision Biosciences, Inc.,
Istari Oncology,
Neoimmunetech,
Macrogenics, Inc..
Immorna's categories are Biotechnology Research
Immorna's founding year is 2019
